>

William Perez - Johnson Johnson Independent Director

<div class='circular--portrait' style='background:#FF6600;color: white;font-size:3em;padding-top: 40px;;'>JNJ</div>
JNJ -- USA Stock  

Fiscal Quarter End: March 31, 2020  

  Director
Mr. William D. Perez is Independent Director of the Company. Mr. Perez served as President and Chief Executive Officer for the Wm. Wrigley Jr. Company from 2006 to 2008. He was a Senior Advisor at Greenhill Co., Inc. from 2010 to 2017. Before joining Wrigley, Mr. Perez served as President and Chief Executive Officer of Nike, Inc. Previously, he spent 34 years with S.C. Johnson Son, Inc., including eight years as its President and Chief Executive Officer. Mr. Perez is a Director at Northwestern Memorial Hospital.
Age: 70  Director Since 2007      
732 214-0332  www.jnj.com

William Perez Latest Insider Activity

Management Efficiency

The company has 30.43 B in debt with debt to equity (D/E) ratio of 50.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Johnson Johnson has Current Ratio of 1.3 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Nazneen RahmanAstrazeneca PLC
2017
Helen HobbsPfizer
2011
Robert HuginAllergan Plc
2019
Karen HornEli Lilly And Company
2012
Ann CairnsAstrazeneca PLC
2014
Etienne DavignonGilead Sciences
N/A
Thomas FreymanAllergan Plc
2018
Suzanne JohnsonPfizer
2007
Peter ArduiniBristol Myers Squibb Company
2016
Pierre LandoltNovartis AG
1996
Roy AndersonGlaxoSmithKline PLC
2007
Lewis CampbellBristol Myers Squibb Company
2014
Srikant DatarNovartis AG
2003
Jamere JacksonEli Lilly And Company
2016
Togo WestBristol Myers Squibb Company
2015
Tony MokAstrazeneca PLC
2019
James BloemAllergan Plc
2013
Ronald BlaylockPfizer
2017
Marcus WallenbergAstrazeneca PLC
1999
Philip BroadleyAstrazeneca PLC
2017
Ron TaylorAllergan Plc
2013

Company Summary

Johnson Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Johnson Johnson operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange.Johnson Johnson (JNJ) is traded on BATS Exchange in USA. It is located in One Johnson and Johnson Plaza, New Brunswick, NJ 08933, United States and employs 135,100 people. Johnson Johnson is listed under Pharmaceutical Products category by Fama And French industry classification.

Johnson Johnson Leadership Team

A Washington, Independent DirectorView
Jennifer Doudna, Independent DirectorView
Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. CommitteeView
William Perez, Independent DirectorView
Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication OfficerView
Marillyn Hewson, Independent DirectorView
Jorge Mesquita, Executive Vice President Worldwide Chairman - ConsumerView
Mary Coleman, Independent DirectorView
Michael Ullmann, VP, General Counsel and Member of Executive CommitteeView
Joaquin Duato, Executive Vice President Worldwide Chairman - PharmaceuticalsView
Kathy Wengel, Executive Vice President Chief Global Supply Chain OfficerView
Jennifer Taubert, Executive Vice President - Worldwide Chairman, PharmaceuticalsView
Mary Beckerle, Independent DirectorView
Sandra Peterson, Group Worldwide Chairman and Member of Executive CommitteeView
Scott Davis, DirectorView
Louise Mehrotra, Vice President Investor RelationsView
Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical DevicesView
Ronald Williams, Independent DirectorView
Kathryn Wengel, Executive Vice President Chief Global Supply Chain OfficerView
D Davis, Independent DirectorView
Hubert Joly, DirectorView
Anne Mulcahy, Lead Independent DirectorView
Joseph Wolk, Chief Financial Officer, Executive Vice PresidentView
Thibaut Mongon, Executive Vice President Worldwide Chairman, ConsumerView
Ian Davis, Independent DirectorView
Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive CommitteeView
Mark McClellan, Independent DirectorView
Charles Prince, Independent DirectorView
Eugene Washington, Independent DirectorView
Dominic Caruso, CFO, VP of Fin. and Member of Executive CommitteeView
Peter Fasolo, Chief Human Resource Officer, Executive Vice PresidentView
Susan Lindquist, Independent DirectorView
Mark Weinberger, DirectorView

Stock Performance Indicators

Current Sentiment - JNJ

Johnson Johnson Investor Sentiment

Predominant part of Macroaxis users are currently bullish on Johnson Johnson. What is your judgment towards investing in Johnson Johnson? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. Please also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.